ACI Logo.png

ACI live programs are certified for CME, CNE, CPE, and MOC credits and are FREE for healthcare professionals, students, patients and patient advocates. Learn to integrate the most up-to-date clinical data for treating a variety of disease states with immunotherapy into your own clinical practice.

The 2025 Advances in Cancer Immunotherapy™ series is supported, in part, through independent medical education grants from AstraZeneca, GSK, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., and Replimune Inc. (supporters as of Apr. 1, 2025).

2025 ACI Series

2025 Enduring Materials

Missed a meeting? Materials are available for purchase for 2 weeks after the program date. Program materials for the Advances in Cancer ImmunotherapyTM programs prior to 2025 are available in the SITC Resource Library below. 

PURCHASE 2025 ENDURING MATERIALS

Please note, if you registered for an ACI meeting, you already have access to the enduring materials for that meeting and should not purchase. Please reach out to education@sitcancer.org with any questions.

Pricing for Enduring Materials

SITC Member Rates

Non-Member Rates

*Student, Patient, Caregiver

Free

Free

Non-Industry Nurse or Pharmacist, Patient Advocate, Foundation/Non-Profit, Patient Advocacy Organization

Free

Free

Clinician, Academic

Free

Free

Government, Non-Industry

Free

Free

Industry (Includes Industry Nurses & Pharmacists) and Investor

$175.00

$250.00

Program Purpose

Specifically designed by the Society for Immunotherapy of Cancer (SITC), the Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified programs, presented by leading authorities in tumor immunology and cancer immunotherapy. Each program will present the latest updates in the specific field addressed by the program, giving a deep dive into practical application, immune-related adverse events, and future trends.

Intended Audience

The ACI programs aim to reach practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Highlights

  • Overview of common approaches to cancer immunotherapy and their related mechanisms
  • Timely updates on the latest clinical advances in the field, including data from recent scientific meetings and clinical trials
  • Dedicated opportunities for clinicians to ask questions and receive direction on difficult cases
  • Strategies for addressing the practical barriers to implementing immunotherapy (operations, reimbursement and management of emerging toxicities)

ACI Partners

SITC has partnered with the Association of Cancer Care Centers (ACCC) and the Advanced Practitioner Society for Hematology and Oncology (APSHO) to provide a comprehensive program providing critical information to incorporate immunotherapy into clinical practice.

ACI Committee

The Society for Immunotherapy of Cancer (SITC) is extremely grateful for the support of the following members of the Planning Committee for the Advances in Cancer Immunotherapy™ educational series.

2025 ACI Committee

  • Marianne Davies, DNP, ACNP, AOCNP, FAAN (Chair)
    Smilow Cancer Hospital at Yale
  • Pradnya Patil, MD, FACP (Co-Chair)
    Dyson Cancer Center
  • Craig Byersdorfer, MD, PhD 
    University of Minnesota
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Bella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Lisa A. Kottschade, APRN, MSN, CNP
    Mayo Clinic
  • Chrystal M. Paulos, PhD
    Winship Cancer Institute at Emory University
  • Mark P. Rubinstein, PhD
    The Ohio State University
  • Iris Sheng, MD
    University Hospitals
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Mays Cancer Center at the University of Texas Health San Antonio

2024 ACI Committee

  • Marianne Davies, DNP, ACNP, AOCNP, FAAN (Chair)
    Smilow Cancer Hospital at Yale
  • Pradnya Patil, MD, FACP (Co-Chair)
    Dyson Cancer Center
  • Craig Byersdorfer, MD, PhD 
    University of Minnesota
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Isabella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Lisa A. Kottschade, APRN, MSN, CNP
    Mayo Clinic
  • Chrystal M. Paulos, PhD
    Winship Cancer Institute at Emory University
  • Mark P. Rubinstein, PhD
    The Ohio State University
  • Iris Sheng, MD
    University Hospitals
  • Raju K. Vaddepally, MD
    Lee Health
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Johns Hopkins University School of Medicine

2023 ACI Committee

2021-2022 ACI Committee

  • Sanjiv S. Agarwala, MD
    Temple University
  • Christian Capitini, MD (Chair)
    University of Wisconsin Carbone Cancer Center
  • Amber Cipriani, PharmD, BCOP, CPP
    UNC Healthcare
  • Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP (Co-chair
    Yale School of Nursing
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Isabella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Paul S. Jansson, MD, MS
    Harvard Medical School
  • Lisa Kottschade, APRN, MSN, CNP
    Mayo Clinic
  • Zihai Li, MD, PhD
    The Ohio State University
  • Pradnya Patil, MD, FACP
    Cleveland Clinic Taussig Cancer Center
  • Chrystal Paulos, PhD
    Emory University
  • Mark Rubinstein, PhD
    Cleveland Clinic Taussig Cancer Center
  • Raju Vaddepally, MD
    Yuma Regional Medical Center Cancer Center
  • Yiping Yang, MD, PhD
    The Ohio State University
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Johns Hopkins University School of Medicine
  • Sanjiv S. Agarwala, MD (Chair)
    Temple University
  • Christian Capitini, MD (Co-chair)
    University of Wisconsin Carbone Cancer Center
  • Amber Cipriani, PharmD, BCOP, CPP
    UNC Healthcare
  • Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP
    Yale School of Nursing
  • Adi Diab, MD
    The University of Texas MD Anderson Cancer Center
  • Sarah B. Dubbs, MD, FAAEM
    University of Maryland School of Medicine
  • Isabella C. Glitza, MD, PhD
    The University of Texas MD Anderson Cancer Center
  • Zihai Li, MD, PhD
    The Ohio State University
  • Pradnya Patil, MD, FACP
    Cleveland Clinic Taussig Cancer Center
  • Chrystal Paulos, PhD
    Emory University
  • Mark Rubinstein, PhD
    Cleveland Clinic Taussig Cancer Center
  • Yiping Yang, MD, PhD
    The Ohio State University
  • Dan P. Zandberg, MD
    UPMC Hillman Cancer Center
  • Lei Zheng, MD, PhD
    Johns Hopkins University School of Medicine

Technology Policy and Information

For optimal completion of this program, the attendee will need a computer/laptop with a strong WiFi connection and the ability to stream video.

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

View the SITC Meeting Code of Conduct.

The 2025 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Advanced Practitioner Society for Hematology and Oncology and the Association of Cancer Care Centers.